郭垣宏
長庚醫療財團法人高雄長庚紀念醫院
國語,英語,閩南語 副教授
一般消化系統疾病診治、病毒性肝炎診治、肝硬化肝衰竭診治、肝癌藥物治療、罕見肝病診治、職業性肝病、診斷性超音波、介入性超音波診治、肝腫瘤消融治療、消化性潰瘍疾病、內視鏡診治、教師發展培育、成人教育
郭垣宏看診時間
| 星期一 | 24 小時營業 |
| 星期二 | 24 小時營業 |
| 星期三 | 24 小時營業 |
| 星期四 | 24 小時營業 |
| 星期五 | 24 小時營業 |
| 星期六 | 24 小時營業 |
| 星期日 | 24 小時營業 |
郭垣宏醫師簡介
現職
- 高雄長庚紀念醫院 內科部副部主任 (2022.07)
- 高雄長庚紀念醫院 胃腸肝膽科系副教授級主治醫師 (2018.07)
- 長庚大學 醫學系 兼任副教授 (2019.08)
學歷
- 中國醫藥大學醫學系畢
- 日本東京順天堂大學短期進修---射頻消融燒灼術 (2015年11月)
- 長庚大學臨床醫學研究所博士班畢(2019.01)
經歷
- 高雄長庚醫院內科部住院醫師
- 高雄長庚醫院胃腸肝膽科系研究員
- 高雄縣鳳山醫院胃腸肝膽科主治醫師
- 正修科技大學兼任講師、助理教授
- 高雄長庚紀念醫院 胃腸肝膽科系病房主任
學會與認證
- 台灣內科醫學會內科專科醫師及指導醫師
- 台灣消化系醫學會消化系內科專科醫師
- 台灣消化系內視鏡醫學會消化系內視鏡專科醫師
- 台灣肝癌醫學會專科醫師
- 台灣腫瘤消融學會認證肝腫瘤消融手術醫師
- 台灣醫學教育學會一般醫學師資
論文及期刊發表
- Kuo YH, Teng W, Chen YH, Lin PT, Wu TH, Su CW, Chen WT, Lin CC, Hung CH, Lu SN, Lin SM, Wang JH*, Lin CY*. Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis. J Clin Transl Hepatol. 2026 Feb 28;14(2):168-176. (SCI)
營養預後指數預測Atezolizumab / Bevacizumab治療肝細胞癌之預後：傾向分數配對分析 - Kuo YH, Teng W(Co-first), Lin PT, Chen YH, Su CW, Shen YL, Huang BS, Wu TH, Cheng JY, Hsieh YC, Chen WT, Hung CH, Lin SM, Lin CC*, Wang JH*, Lin CY*. Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Liver Int. 2026 Jan;46(1):e70465. (SCI)
質子束放射治療可提升 Atezolizumab／Bevacizumab 治療晚期肝細胞癌的臨床療效：一項傾向分數分析 - Lee HY, Chang CD, Chen YH, Tsai MC, Wang JH, Lu SN, Hu TH, Hung CH, Chen CH, Kuo YH*. Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan. Gut Liver. 2025 Nov 15;19(6):878-888. (SCI)
動態肌肉萎縮預測接受第一線Lenvatinib治療之無法手術切除肝細胞癌病患的預後：一項台灣的回溯性研究 - Kuo YH*, Chen YH, Tsai MC, Lu SN, Hu TH, Hung CH, Chen CH, Wang JH*. Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma. Am J Cancer Res. 2025 Feb 15;15(2):811-823. (SCI)
比較健保給付的Lenvatinib與自費使用的Atezolizumab/Bevacizumab在不可切除肝癌患者中的療效 - Sou FM, Chen CH, Huang PY, Tsai MC, Yen YH, Lu SN, Hung CH, Kuo YH*. Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct-acting antivirals. Adv Dig Med. 2024 Dec;11:189–195.
在直接作用抗病毒藥物時代，接受鴉片類替代物治療的藥物成癮患者的C型肝炎病毒消除策略 - Hsiao YW, Sou FM, Wang JH, Chen YH, Tsai MC, Hu TH, Hung CH, Chen CH, Kuo YH*. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. Kaohsiung J Med Sci. 2023 Dec;39(12):1233-1242. (SCI)
控制良好的病毒血症可減少接受樂衛瑪(Lenvatinib)治療的慢性病毒性肝炎病人肝癌的惡化 - Kuo YH, Huang TH, Yen YH, Lu SN, Wang JH, Hung CH, Chen CH, Tsai MC, Kee KM*. Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation. Cancers. 2023 Jun 12;15(12):3156. (SCI)
列線圖預測早期肝癌經射頻消融後的長期存活率 - Kuo YH, Huang TH, Wang JH, Chen YY, Tsai MC, Chen YH, Lu SN, Hu TH, Chen CH, Hung CH*. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers (Basel). 2022 Aug 17;14(16):3971. (SCI)
控制良好的病毒血症可預測接受蕾莎瓦治療的慢性病毒性肝炎病人肝癌的癒後 - Chen HY, Kee KM, Lu SN, Wang JH, Chen CH, Hung CH, Yen YH, Kuo YH*. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. J Formos Med Assoc. 2022 Apr;121(4):778-786. (SCI)
整合白蛋白-黃疸分級(ALBI GRADE)及上限7準則 (UP-TO-7 )來預測肝癌中期病患之預後 - Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH*. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. Kaohsiung J Med Sci. 2022 Mar;38(3):268-276. (SCI)
基於肝硬度的分數可預測根除Ｃ型肝炎病毒後的肝臟相關並發症風險 - Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH*. Real world Lenvatinib versus Sorafenib in patients with advanced hepatocellular carcinoma: A Propensity Score Matching analysis. Front Oncol. 2021 Oct 25;11:737767. (SCI)
現實世界晚期肝癌病人使用樂衛瑪(LENVATINIB)和蕾莎瓦(SORAFENIB)的比較- 一個傾向分數配對分析 - Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN*, Kuo YH*. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci. 2021 Oct;37(10):894-902. (SCI)
蕾莎瓦在Ｂ型肝炎病毒或C型肝炎病毒相關的肝癌中使用的結果：傾向分數配對研究 - Kuo YH, Yen YH, Chen YY, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH*. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol. 2021 May 31;11:683341. (SCI)
肝癌病人蕾莎瓦治療失敗後, 使用保疾伏和癌瑞格的比較 - Kuo YH , Wang JH, Hung CH, Lu SN, Hu TH*,Chen CH*.Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int. 2021 Apr;15(2):301-309. (SCI)
合併停藥時B肝表面抗原與基線B肝病毒核心相關抗原可減少惠立妥停藥後B肝復發率 - Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH*. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs. 2020 Feb;38(1):202-210. (SCI)
直接抗病毒藥物對C型肝炎相關肝癌經根除性治療後的影響 - Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN*. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One. 2019 Oct 22;14(10):e0222196. (SCI)
在大型社區篩檢，使用APRI和FIB4來偵測慢性C型肝炎 - Kuo YH, Lu SN*. Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. Aliment Pharmacol Ther. 2019 Jan;49(2):233-234. (SCI)
- Kuo YH, Lu SN*. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors' reply. Aliment Pharmacol Ther. 2018 Nov;48(10):1162-1163. (SCI)
- Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, Lu SN*. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002. (SCI)
台灣南部慢性病毒性肝炎與代謝症候群的關聯:一項大型人口基底的研究 - Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN*. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs. 2018 Apr;36(2):307-314. (SCI)
雷沙瓦單一治療在肝門靜脈栓塞肝癌的預後 - Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN* . Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981. (SCI)
用ALBI GRADE預測晚期肝癌病人的預後 - Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. PLoS One. 2016 May 13;11(5):e0155544. (SCI)
社區老年慢性肝炎者有代謝症候群的相關因子 - Kuo YH, Lu SN*. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. Kaohsiung J Med Sci. 2015 July; 31(7):386-387. (SCI) (letter)
定量B型肝炎抗原在追蹤社區研究B型肝炎病人的角色 - Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, Lu SN*. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. PLoS One. 2015 May 13;10(5):e0126031. (SCI)
社區ANTI-HCV陽性居民篩檢後照護策略的比較：簡單通知、主動轉介或可近性醫療照顧 - Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Lu SN*. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort. Kaohsiung J Med Sci. 2015 Feb; 31(2): 102–107. (SCI)
慢性B型肝炎帶原者血清中定量表面抗原與病毒量變化: 一個老年族群的追蹤研究 - Kuo YH, Chung KC, Hung CH, Lu SN, Wang JH*. The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences. 2014 Nov; 30(11): 559-565.
全身麻醉對於肝癌射頻燒灼術的影響 - Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH*. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014 Mar 28;9(3):e93160.
慢性B型肝炎病人接受貝樂克治療後肝臟硬度值的變化和其相關因子 - Wang JH*#, Kuo YH#, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013 Jun;45(6):510-515. (SCI) (#: co-first author)
外科切除肝癌改善經選擇的BCLC晚期肝癌病人的存活 - Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN*. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012 Jun;50(6):1989-93. (SCI)
C型肝炎核心抗原是對社區篩檢的一個合適標記嗎？ - Kuo YH, Chuang TW, Hung CH*, Chen CH, Wang JH, Hu TH, Lu SN, Lee CM. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. J Formos Med Assoc. 2011 Jun;110(6):363-71. (SCI)
慢性C型肝炎病人低血脂成功清除病毒後改善 - Kuo YH, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH*. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int. 2010 Oct 8;4(4):700-6. (SCI)
以肝臟硬度測量值評估慢性肝炎病人肝癌發生風險 - Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH*. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010 Mar;46(4):744-51. (SCI)
肝癌篩檢即是當治療改善肝硬化病人存活率 - Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM*. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45(1):75-81. (SCI)
慢性B型肝炎E抗原陽性病人延長肝安能強化治療可達到較佳的E抗原持續反應 - Kuo YH, Kuo CM, Chou YP, Chuah SK, Chiu YC, Wu KL*, Rayner CK, Eng HL. Gastric ulcer infected with candida: risk factors and endoscopic appearance. Taiwan J Gastroenterol 2009, 26(4):285-90.
胃潰瘍合併念珠菌感染的相關因子與內視鏡表徵 - Kuo YH, Wang JH, Lu SN, Hung CH*, Wei YC, Hu TH, Chen CH, Yen YH, Lee CM, Eng HL. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound. 2009 Mar-Apr;37(3):132-7. (SCI)
肝臟局部增生性結節自然病程：腹部超音波長期追蹤 - Kuo YH, Wang JH*, Hu TH, Lee CM. Primary Hepatocellular Carcinoma in Ectopic Liver and Later Metastasis to Mother Liver: A Case Report and Review of the Literature. J Intern Med Taiwan 2008, 19(1):422-7.
異位性肝癌術後長期追蹤發生原發性肝癌: 病例報告與文獻整理